Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: In the NETTER-1 study, peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE increased progression-free survival (PFS) and time to deterioration in quality of life (QoL) in patients with advanced midgut neuroendocrine tumours (NETs), compared with octreotide.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Keywords: 177Lu-DOTATATE, metastases, quality of life,
Introduction: Peptide receptor radionuclide therapy (PRRT) usually leads to stable rather than decreased lesion size in neuroendocrine tumors (NETs), therefore RECIST criteria are not used to assess early response to treatment.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Song H, Kunz P, Fisher G, Franc B, Moradi F,
Keywords: PRRT, 68Ga-DOTATATE PET/CT, Neuroendocrine tumor,
Introduction: Patients with neuroendocrine tumors have few treatment options after progression to first-line somatostatin analogues.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Carmona Bayonas A
Authors: Carmona-Bayonas A, Mitjavila Casanovas M, Belló P, Percovich J, Prieto A,
Keywords: PRRT, 177Lu-DOTATATE, radionuclide,
Introduction: 177Lu-DOTATATE is an effective therapy for somatostatin receptor-positive neuroendocrine tumors (NETs). Often enough 177Lu-DOTATATE is used as the last treatment resort in advanced NET.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Song H, Kunz P, Franc B, Moradi F, Fisher G,
Keywords: 177Lu-DOTATATE, PRRT, 68Ga-DOTATATE PET, Chromogranin A, 68Ga-DOTATATE avid tumor volume,
Introduction: Pancreatic neuroendocrine neoplasm (pNEN) patients often present with locally advanced or metastatic disease. The objective response rate of peptide receptor radionuclide therapy (PRRT) in pNENs is 55%. Therefore, PRRT may be a possibility for patients who are not eligible for upfront curative surgery.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Minczeles N, van Eijck C, van Gils M, van Velthuysen M, Nieveen van Dijkum E,
Keywords: neoadjuvant, peptide receptor radionuclide therapy, neuroendocrine, pancreas, surgery,